Previous studies have confirmed that HER2/EGFR activity is essential for the TGFβ-stimulated migration of breast cancer cells, while the inhibition of HER2/EGFR activity can enhance the inhibitory effects of TGFβ on cellular processes. This evidence concerns the gene TGFB1 and breast carcinoma.